MCID: GRV008
MIFTS: 44

Graves Disease 1 malady

Categories: Endocrine diseases, Rare diseases, Immune diseases

Aliases & Classifications for Graves Disease 1

Summaries for Graves Disease 1

OMIM : 54 Graves disease is an autoimmune disorder in which antibodies to the thyrotropin receptor (TSHR; 603372) result in... (275000) more...

MalaCards based summary : Graves Disease 1, also known as thyrotoxicosis, is related to endemic goiter and neonatal thyrotoxicosis, and has symptoms including muscle weakness, hyperhidrosis and hyperreflexia. An important gene associated with Graves Disease 1 is GRD1 (Graves Disease, Susceptiblity To, 1), and among its related pathways/superpathways are Allograft rejection and Insulin secretion. The drugs Propylthiouracil and Ursodeoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include thyroid and heart, and related phenotypes are growth/size/body region and endocrine/exocrine gland

Disease Ontology : 12 A thyroid gland disease that is characterized by excess thyroid hormone.

Related Diseases for Graves Disease 1

Diseases in the Graves' Disease family:

Graves Disease 1 Graves Disease 2

Diseases related to Graves Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 226)
id Related Disease Score Top Affiliating Genes
1 endemic goiter 29.5 SERPINA7 TG TPO TSHR
2 neonatal thyrotoxicosis 12.1
3 thyroid carcinoma with thyrotoxicosis 12.0
4 subacute thyroiditis 11.1
5 stiff-person syndrome 10.8
6 mccune-albright syndrome, somatic, mosaic 10.8
7 hypokalemic periodic paralysis, type 1 10.8
8 graves' disease 10.6
9 hyperthyroidism 10.6
10 thyroiditis 10.5
11 acute hemorrhagic encephalitis 10.3 TG TSHR
12 gastrinoma 10.3 TG TSHR
13 mesocardia 10.2 TG TSHR
14 echinostomiasis 10.2 SERPINA7 TG
15 parachordoma 10.2 TG TSHR
16 atheroembolism of kidney 10.2 TG TRH
17 fibrous meningioma 10.2 TG TPO
18 potter's syndrome 10.2 TSHR TXNRD2
19 premature closure of the arterial duct 10.2 TG TPO
20 neuronopathy, distal hereditary motor, type viia 10.2 SERPINA7 TG TSHR
21 frontal sinusitis 10.1 TG TPO
22 acute laryngitis 10.1 TG TSHR
23 neuhauser daly magnelli syndrome 10.1 TG TPO TSHR
24 caudal regression syndrome 10.1 TG TPO
25 conjunctival deposit 10.1 TG TPO TSHR
26 nodular prostate 10.1 TG TPO TSHR
27 exanthema subitum 10.1 TG TPO TSHR
28 peritoneal serous papillary adenocarcinoma 10.1 TG TPO TSHR
29 commensal bacterial infectious disease 10.1 TG TPO TSHR
30 tick paralysis 10.1 TG THRB TPO
31 choreoathetosis, hypothyroidism, and neonatal respiratory distress 10.1 TG TPO TSHR
32 color blindness 10.1 TG TPO
33 tenosynovitis of foot and ankle 10.1 TG TPO TSHR
34 extrahepatic bile duct adenocarcinoma 10.1 SERPINA7 TG TPO
35 non-distal monosomy 10q 10.1 TG TPO TSHR
36 gershoni-baruch syndrome 10.1 THRB TRH TXNRD2
37 diabetes mellitus, insulin-dependent, 12 10.1 TG TPO TSHR
38 olfactory nerve neoplasm 10.1 INS TRH
39 congenital nonspherocytic hemolytic anemia 10.1 SERPINA7 TPO TRH
40 protein s deficiency 10.1 INS TRH
41 dysautonomia, familial 10.0 TG TPO
42 goiter 10.0
43 diencephalic neoplasm 10.0 INS SERPINA7 TRH
44 hypothyroidism 10.0
45 background diabetic retinopathy 10.0 SERPINA7 TG TPO TSHR
46 krabbe disease 10.0 SERPINA7 TG TPO TSHR
47 mixed eosinophil-basophil adenoma 10.0 SERPINA7 TG TPO TSHR
48 janus kinase-3 deficiency 10.0 SERPINA7 TG TPO TSHR
49 muscular dystrophy-dystroglycanopathy , type a, 10 10.0 TG THRB TPO TSHR
50 repetitive motion disorders 10.0 CACNA1S SCN4A

Graphical network of the top 20 diseases related to Graves Disease 1:



Diseases related to Graves Disease 1

Symptoms & Phenotypes for Graves Disease 1

Symptoms by clinical synopsis from OMIM:

275000

Clinical features from OMIM:

275000

Human phenotypes related to Graves Disease 1:

32 (show all 15)
id Description HPO Frequency HPO Source Accession
1 muscle weakness 32 HP:0001324
2 hyperhidrosis 32 HP:0000975
3 hyperreflexia 32 HP:0001347
4 abnormality of metabolism/homeostasis 32 HP:0001939
5 irritability 32 HP:0000737
6 weight loss 32 HP:0001824
7 congestive heart failure 32 HP:0001635
8 goiter 32 HP:0000853
9 proptosis 32 HP:0000520
10 polyphagia 32 HP:0002591
11 hyperactivity 32 HP:0000752
12 graves disease 32 HP:0100647
13 onycholysis 32 HP:0001806
14 abnormality of abdomen morphology 32 HP:0001438
15 pretibial myxedema 32 HP:0200028

MGI Mouse Phenotypes related to Graves Disease 1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.76 CACNA1S INS SCN4A TG THRB TPO
2 endocrine/exocrine gland MP:0005379 9.73 INS TG THRB TPO TRH TSHR
3 homeostasis/metabolism MP:0005376 9.65 TPO TRH TSHR TXNRD2 CACNA1S INS
4 nervous system MP:0003631 9.23 CACNA1S INS SLC16A2 TG THRB TRH

Drugs & Therapeutics for Graves Disease 1

Drugs for Graves Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 290)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propylthiouracil Approved Phase 4,Phase 3,Phase 2 51-52-5 657298
2
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
3
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
4
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
5
Propranolol Approved, Investigational Phase 4 525-66-6 4946
6
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
7
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
8
Ephedrine Approved Phase 4 299-42-3 9294
9
Pseudoephedrine Approved Phase 4 90-82-4 7028
10
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
11
Armodafinil Approved, Investigational Phase 4,Phase 3 112111-43-0
12
Modafinil Approved, Investigational Phase 4,Phase 3 68693-11-8 4236
13
Celecoxib Approved, Investigational Phase 4,Phase 2 169590-42-5 2662
14
Ibuprofen Approved Phase 4 15687-27-1 3672
15
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
16
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
17 Antimetabolites Phase 4,Phase 3,Phase 2
18 Antithyroid Agents Phase 4,Phase 3,Phase 1,Phase 2
19 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
20 Hormones Phase 4,Phase 3,Phase 2,Phase 1
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
22 Cholagogues and Choleretics Phase 4
23 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
24 Liver Extracts Phase 4,Phase 3
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Anti-Infective Agents, Local Phase 4
27 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
28 Adrenergic Agents Phase 4,Phase 1
29 Adrenergic Antagonists Phase 4
30 Adrenergic beta-1 Receptor Antagonists Phase 4
31 Adrenergic beta-Antagonists Phase 4
32 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
33 Analgesics, Non-Narcotic Phase 4,Phase 2
34 Anti-Arrhythmia Agents Phase 4
35 Antihypertensive Agents Phase 4
36 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
38 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Cyclooxygenase Inhibitors Phase 4,Phase 2
41 Neurotransmitter Agents Phase 4,Phase 2,Phase 1
42 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Sympatholytics Phase 4
44 Vasodilator Agents Phase 4,Phase 2
45 Benzalkonium Compounds Phase 4
46 Dinoprost Phase 4
47 Lubricant Eye Drops Phase 4,Phase 2
48 Nasal Decongestants Phase 4
49 Ophthalmic Solutions Phase 4,Phase 2
50 Oxytocics Phase 4

Interventional clinical trials:

(show top 50) (show all 125)
id Name Status NCT ID Phase
1 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4
2 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4
3 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4
4 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4
5 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4
6 A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints Completed NCT00276510 Phase 4
7 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4
8 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4
9 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Recruiting NCT01738243 Phase 4
10 Antithyroid Drug Treatment of Thyrotoxicosis in Young People Completed NCT01436994 Phase 3
11 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3
12 Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Completed NCT00228553 Phase 3
13 Probiotic Lozenge Reduce Streptococcus Mutans in Plaque in Orthodontic Bracket Patients Completed NCT02357771 Phase 3
14 Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site Completed NCT00193596 Phase 3
15 Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection Completed NCT01641640 Phase 3
16 Phase IIIB Switching From Intravenous to Subcutaneous Study Completed NCT00663702 Phase 3
17 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00462709 Phase 3
18 Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon Completed NCT01542788 Phase 3
19 Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3
20 Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens Completed NCT01096615 Phase 3
21 Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia. Completed NCT00423605 Phase 3
22 A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia Completed NCT00371137 Phase 3
23 Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee Completed NCT00531427 Phase 3
24 Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia Completed NCT00803023 Phase 3
25 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3
26 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3
27 Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients Recruiting NCT02944045 Phase 3
28 Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer Recruiting NCT02853604 Phase 3
29 Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease Recruiting NCT02596893 Phase 3
30 A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease Recruiting NCT02641392 Phase 3
31 CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Recruiting NCT02670083 Phase 3
32 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Recruiting NCT02548351 Phase 3
33 Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Di Recruiting NCT02760433 Phase 3
34 Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease Recruiting NCT02760407 Phase 3
35 An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia Recruiting NCT02569398 Phase 2, Phase 3
36 A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease Active, not recruiting NCT01224106 Phase 3
37 A Study of Gantenerumab in Participants With Mild Alzheimer Disease Active, not recruiting NCT02051608 Phase 3
38 DO-HEALTH / Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial Active, not recruiting NCT01745263 Phase 3
39 A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02). Active, not recruiting NCT02480153 Phase 3
40 A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02) Active, not recruiting NCT02222493 Phase 3
41 A Study Comparing ABT-494 to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug Enrolling by invitation NCT03104400 Phase 3
42 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3
43 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3
44 Interest of Using Balanced Fluid for Infusion at the Early Phase of an Acute Cranial Trauma for Limiting Hyperchloremic Acidosis Terminated NCT00847977 Phase 3
45 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
46 Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia Unknown status NCT01039363 Phase 2
47 Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient? Completed NCT01247077 Phase 2
48 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients Completed NCT02993302 Phase 2
49 Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2
50 Radioactive Iodide Therapy for Pediatric Graves' Disease Completed NCT01269749 Phase 2

Search NIH Clinical Center for Graves Disease 1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: thyrotoxicosis

Genetic Tests for Graves Disease 1

Anatomical Context for Graves Disease 1

MalaCards organs/tissues related to Graves Disease 1:

39
Thyroid, Heart

Publications for Graves Disease 1

Variations for Graves Disease 1

Expression for Graves Disease 1

Search GEO for disease gene expression data for Graves Disease 1.

Pathways for Graves Disease 1

GO Terms for Graves Disease 1

Biological processes related to Graves Disease 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone-mediated signaling pathway GO:0009755 9.32 TRH TSHR
2 membrane depolarization during action potential GO:0086010 9.26 CACNA1S SCN4A
3 hormone biosynthetic process GO:0042446 9.16 TG TPO
4 thyroid hormone transport GO:0070327 8.96 SERPINA7 SLC16A2
5 negative regulation of feeding behavior GO:2000252 8.62 INS TRH

Molecular functions related to Graves Disease 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 INS TG TRH

Sources for Graves Disease 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....